The FDA CRL introduces significant regulatory uncertainty for GTx-104's approval timeline. The Type A meeting outcome (expected within weeks) will determine whether resubmission is feasible or requires additional trials. With $17M cash and no approved product revenue, the stock is binary on CRL resolution. Monitor for Type A meeting minutes and any NDA resubmission timeline.
Price Chart
Executive Summary
Grace Therapeutics reported FY2026 net loss of $7.8M ($0.47/share), improving from $9.6M ($0.79/share) in FY2025, driven by lower R&D expenses as the pivotal Phase 3 STRIVE-ON trial closed. The key event is the April 2026 FDA Complete Response Letter for GTx-104 NDA, citing CMC and non-clinical deficiencies, with a Type A meeting scheduled to clarify the resubmission path. Cash at $17.0M provides ~12-month runway through the CRL response period.
Key Financial Metrics
Key Facts
- Net loss for FY2026: $7.8M ($0.47/share) vs $9.6M ($0.79/share) in FY2025
- FDA issued Complete Response Letter for GTx-104 NDA on April 23, 2026, citing CMC and non-clinical deficiencies
- Cash and cash equivalents at March 31, 2026: $17.0M, down from $22.1M at March 31, 2025
- Type A meeting with FDA scheduled to clarify path to NDA resubmission
- R&D expenses decreased 75% to $2.4M from $9.5M as STRIVE-ON trial closed
- No clinical deficiencies were identified in the CRL
Financial Impact
Net loss improved $1.8M YoY; cash burn $5.1M; $17.0M cash runway ~12 months
Risk Factors
- CRL may require additional clinical trials or CMC work beyond current cash runway
- No approved products or revenue; cash burn rate may accelerate with pre-commercial planning
- Warrant overhang: $15.0M potential gross proceeds from February 2025 warrants expire 60 days post-NDA approval or Sept 2028
- Deprioritized GTx-102 and GTx-101 programs limit pipeline diversification
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001140361-26-025667 |
| Document: ef20076145_8k.htm | 0001140361-26-025667 |
| Document: 0001140361-26-025667-index-headers.html | 0001140361-26-025667 |
| Document: 0001140361-26-025667-index.html | 0001140361-26-025667 |
| Document: 0001140361-26-025667.txt | 0001140361-26-025667 |
| 8-K Data (Synthetic) | 0001140361-26-025667 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 10, 2026 6w ago | Insider Cluster | $2.26 $2.22 | ▼ −1.77% | ▼ −2.62% | $1.93 (−14.60%) |
Aug 13, 2026 10w ago | 8-K | $2.07 $2.16 | ▲ +4.35% | ▲ +4.55% | $1.93 (−6.76%) |
Aug 13, 2026 10w ago | Press Release | $2.07 $2.16 | ▲ +4.35% | ▲ +4.55% | $1.93 (−6.76%) |
Aug 4, 2026 11w ago | Press Release | $2.14 $2.12 | ▼ −0.93% | ▼ −0.77% | $1.93 (−9.81%) |
Jul 28, 2026 12w ago | 8-K | $2.25 $2.08 | ▼ −7.56% | ▼ −6.02% | $1.93 (−14.22%) |
Jun 18, 2026 18w ago | 8-K | $2.38 $2.26 | ▼ −5.04% | ▼ −4.73% | $1.93 (−18.91%) |
Jun 18, 2026 18w ago | 8-K | $2.38 $2.26 | ▲ +5.04% | ▲ +4.73% | $1.93 (+18.91%) |
Jun 18, 2026 18w ago | Press Release | $2.38 $2.26 | ▲ +5.04% | ▲ +4.73% | $1.93 (+18.91%) |
Jun 5, 2026 20w ago | 8-K | $2.30 $2.33 | ▲ +1.30% | ▲ +1.60% | $1.93 (−16.09%) |
Apr 27, 2026 26w ago | 8-K | $2.16 $2.10 | ▲ +2.78% | ▲ +2.29% | $1.93 (+10.65%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers